drugset / Trial / NCT05873192
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.
Timeline
- Start
- 2025-06-03
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | — | Oral |
| Background | Degarelix | Other / unclassified | — | Oral |
| Background | Enzalutamide | Other / unclassified | — | Oral |
| Background | Luprolide | Unknown | — | Oral |